Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma

Journal of Vascular and Interventional Radiology

Volumn 22, Issue 11, 2011, Pages 1545-1552

  Sacco, Rodolfo ^a,b   Bargellini, Irene ^a   Bertini, Marco ^a   Bozzi, Elena ^a   Romano, Antonio ^a   Petruzzi, Pasquale ^a   Tumino, Emanuele ^a   Ginanni, Barbara ^a   Federici, Graziana ^a   Cioni, Roberto ^a   Metrangolo, Salvatore ^a   Bertoni, Michele ^a   Bresci, Giampaolo ^a   Parisi, Giuseppe ^a   Altomare, Emanuele ^b   Capria, Alfonso ^a   Bartolozzi, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

alanine aminotransferase; ALT; Barcelona Clinic Liver Cancer; BCLC; DEB; drug eluting bead; HCC; hepatocellular carcinoma

Indexed keywords

DOXORUBICIN; IODINATED POPPYSEED OIL; LIPIODOL ULTRA FLUID; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG ELUTING BEAD; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG CARRIERS; FEMALE; HEPATIC ARTERY; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 80054925991     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2011.07.002     Document Type: Article

References (24)

1. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171 (Pubitemid 34454013)
2. J.M. Llovet, M.I. Real, X. Montaa Barcelona Liver Cancer Group Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739 (Pubitemid 34607087)
3. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442 (Pubitemid 36152543)
4. J. Bruix, M. Sherman, J.M. Llovet EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430 (Pubitemid 32844200)
5. J. Bruix, M. Sherman Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236 (Pubitemid 43112690)
6. K. Malagari, K. Chatzimichael, and E. Alexopoulou Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients Cardiovasc Intervent Radiol 31 2008 269 280
7. M. Varela, M.I. Real, and M. Burrel Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481 (Pubitemid 46201723)
8. K. Malagari, M. Pomoni, and A. Kelekis Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2010 541 551
9. J. Lammer, K. Malagari, T. Vogl PRECISION V Investigators Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
10. D.B. Brown, C.E. Fundakowski, and M. Lisker-Melman Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma J Vasc Interv Radiol 15 2004 1209 1218 (Pubitemid 39487850)
11. Cancer of the Liver Italian Program (CLIP) Investigators Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma Hepatology 31 2000 840 845
12. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
13. D.B. Brown, J.F. Cardella, and D. Sacks Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy J Vasc Interv Radiol 20 Suppl 7 2009 S219 S226
14. J.M. Llovet, A. Di Bisceglie, and J. Bruix Panel of Experts in HCC-Design Clinical Trials Design and end-points of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
15. S.H. Kim, W.J. Lee, H.K. Lim, and J.H. Lim Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography J Comput Assist Tomogr 31 2007 198 203 (Pubitemid 46573355)
16. D.B. Brown, J.F. Geschwind, M.C. Soulen, S.F. Millward, and D. Sacks Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies J Vasc Interv Radiol 20 Suppl 7 2009 S317 S323
17. A.L. Lewis, M.V. Gonzalez, and A.W. Lloyd DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization J Vasc Interv Radiol 17 2006 335 342 (Pubitemid 44341453)
18. K. Hong, A. Khwaja, E. Liapi, M.S. Torbenson, C.S. Georgiades, and J.F. Geschwind New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer Clin Cancer Res 12 2006 2563 2567
19. S.Y. Song, W.J. Chung, and J.K. Han Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome J Vasc Interv Radiol 12 2001 313 320
20. J.F. Geschwind, S. Kaushik, D.E. Ramsey, M.A. Choti, E.K. Fishman, and H. Kobeiter Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors J Vasc Interv Radiol 13 2002 1163 1166 (Pubitemid 35332903)
21. R. Sacco, M. Bertini, and P. Petruzzi Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study World J Gastroenterol 15 2009 1843 1848
22. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC) J Surg Oncol 101 2010 476 480
23. Y.S. Kim, H. Rhim, and H.K. Lim Completeness of treatment in hepatocellular carcinomas treated with image-guided tumour therapies: evaluation of positive predictive value of contrast-enhanced CT with histopathologic correlation in the explanted liver specimen J Comput Assist Tomogr 30 2006 578 582 (Pubitemid 44091511)
24. S.A. Shah, J.C. Tan, and I.D. McGilvray Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma Transplantation 81 2006 1633 1639 (Pubitemid 43948294)